Search Medical Condition
Please enter condition
Please choose location

null Clinical Trials

A listing of null medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (17) clinical trials

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.


Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

The drug being tested in this study is called brentuximab vedotin. This study will look at efficacy, safety and PK of brentuximab vedotin in Chinese participants with relapsed/refractory CD30+ HL or sALCL. The study will enroll approximately 30 patients. Participants will receive: • Brentuximab vedotin 1.8 mg/kg All participants will ...


Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

PRIMARY OBJECTIVES: I. To evaluate the efficacy of the combination of romidepsin plus lenalidomide in patients with previously untreated peripheral T-cell lymphoma (PTCL). SECONDARY OBJECTIVES: I. Evaluate the safety of the combination of romidepsin and lenalidomide. II. Further evaluate efficacy of the combination of romidepsin and lenalidomide. III. Evaluate the ...


ARQ 751 in Solid Tumors With AKT1 2 3 Genetic Alterations Activating PI3K Mutations PTEN-null or Other Known Actionable PTEN Mutations

This is an open-label, Phase 1, dose escalation study of ARQ 751 administered orally to subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations


Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Background The treatment of the intermediate and aggressive non-Hodgkin's lymphomas in adults and children commonly induces complete responses in a sizable fraction of the treated population, and about 2/3 of the complete responders appear to have prolonged disease-free survival. The present study assesses the activity and tolerability in previously untreated ...


Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

PRIMARY OBJECTIVES: I. To determine if vitamin D replacement in vitamin D insufficient patients with newly diagnosed untreated diffuse large B-cell lymphoma (DLBCL) can improve event free survival at 12 months to be equivalent to that of a control population of vitamin D sufficient patients. (Study I) II. To assess ...

Phase N/A

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...


Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

Cytarabine in combination with an anthracycline is a frequently used chemotherapy platform for both newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) and other hematologic malignancies. Synergistic antitumor activity has been demonstrated between cytarabine and daunorubicin that is dependent upon the ratio of the drugs with the best therapeutic effect ...


A clinical trial seeking patients for a research study for the treatment of Recurrent Mycosis Fungoides/Sezary Syndrome, ESSENTIAL THROMBOCYTHEMIA, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Lymphoblastic Lymphoma, Refractory Cytopenia With Multilineage Dysplasia, anaplastic large cell lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Anemia with Excess of Blasts, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Waldenstrom's Macroglobulinemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Childhood Myelodysplastic Syndromes, Recurrent Childhood Acute Myeloid Leukemia, chronic phase chronic myelogenous leukemia, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Relapsing Chronic Myelogenous Leukemia, Chronic myelomonocytic leukemia, Recurrent Adult T-cell Leukemia/Lymphoma, de Novo Myelodysplastic Syndromes, Childhood Chronic Myelogenous Leukemia, Myelosclerosis with myeloid metaplasia, Testicular Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Intraocular Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Secondary Acute Myeloid Leukemia, Hepatosplenic T-cell Lymphoma, Polycythemia Vera, Blast Crisis, T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, Angioimmunoblastic Lymphadenopathy, Refractory Hairy Cell Leukemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Multiple Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Noncutaneous Extranodal Lymphoma, Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Adult Acute Myeloid Leukemia With Del(5q), Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Post-transplant Lymphoproliferative Disorder, Small Intestine Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent/Refractory Childhood Hodgkin Lymphoma, Childhood Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Nodal Marginal Zone B-cell Lymphoma, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...


Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Phase N/A